# EDGAR Filing Document

**Accession Number:** 0001382333
**File Stem:** 0001382333-23-000001
**Filing Date:** 2023-1
**Character Count:** 6412
**Document Hash:** dacf3c848a2d79b0f22a7893e7a843a1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001382333-23-000001.hdr.sgml**: 20230104

**ACCESSION NUMBER**: 0001382333-23-000001

**CONFORMED SUBMISSION TYPE**: SC 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230104

**DATE AS OF CHANGE**: 20230104

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Esperion Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001434868
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-87536
- **FILM NUMBER:** 23505582

**BUSINESS ADDRESS:**
- **STREET 1:** 3891 RANCHERO DRIVE, SUITE 150
- **CITY:** ANN ARBOR
- **STATE:** MI
- **ZIP:** 48108
- **BUSINESS PHONE:** 734-887-3903

**MAIL ADDRESS:**
- **STREET 1:** 3891 RANCHERO DRIVE, SUITE 150
- **CITY:** ANN ARBOR
- **STATE:** MI
- **ZIP:** 48108

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HDL THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 20080513
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Meditor Group Ltd
- **CENTRAL INDEX KEY:** 0001382333
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** D0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A

**BUSINESS ADDRESS:**
- **STREET 1:** WESSEX HOUSE, 3RD FLOOR
- **STREET 2:** 45 REID STREET
- **CITY:** HAMILTON
- **STATE:** D0
- **ZIP:** HM12
- **BUSINESS PHONE:** 4412792080

**MAIL ADDRESS:**
- **STREET 1:** WESSEX HOUSE, 3RD FLOOR
- **STREET 2:** 45 REID STREET
- **CITY:** HAMILTON
- **STATE:** D0
- **ZIP:** HM12

```

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

	Esperion Therapeutics, Inc.

	(Name of Issuer)

	Common Stock

	(Title of Class of Securities)

	29664W105

	(CUSIP Number)

	December 31, 2022

	(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which
this Schedule is filed:

	[   ]Rule 13d-1(b)

	[ X ]Rule 13d-1(c)

	[   ]Rule 13d-1(d)

-------------------------------------------------------------

CUSIP No. 29664W105

1. Names of Reporting Persons.

   (i)	Meditor Group Ltd.
   (ii)	Meditor European Master Fund Ltd.

  I.R.S. Identification Nos. of above persons (entities only).

   (i)	.................
   (ii) .................

2. Check the Appropriate Box if a Member of a Group (See Instructions)

	[   ](a)

	[   ](b)

3. SEC Use Only

4. Citizenship or Place of Organization

   (i)	Bermuda
   (ii)	Bermuda

Number of Shares Beneficially Owned by Each Reporting Person With:

5. Sole Voting Power

   (i) 	.........
   (ii) .........

6. Shared Voting Power

   (i)	4,468,835
   (ii)	4,468,835

7. Sole Dispositive Power

   (i)	.........
   (ii) .........

8. Shared Dispositive Power

   (i) 	4,468,835
   (ii)	4,468,835

9. Aggregate Amount Beneficially Owned by Each Reporting Person

   (i) 	4,468,835
   (ii)	4,468,835

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares

	[   ]

11. Percent of Class Represented by Amount in Row (9)

   (i)	6.1%
   (ii) 6.1%

12. Type of Reporting Person (See Instructions)

   (i) 	CO
   (ii)	CO

-------------------------------------------------------------

Item 1.

(a) Name of Issuer

	Esperion Therapeutics, Inc.

(b) Address of Issuer's Principal Executive Offices

    3891 Ranchero Drive, Suite 150, Ann Arbor, MI

Item 2.

(a) Name of Person Filing

   (i)	Meditor Group Ltd.
   (ii) Meditor European Master Fund Ltd.

(b) Address of Principal Business Office or, if none, Residence

   (i) 	Wessex House, 3rd Floor, 45 Reid Street, Hamilton HM12, Bermuda
   (ii) Wessex House, 3rd Floor, 45 Reid Street, Hamilton HM12, Bermuda

(c) Citizenship

   (i) 	Bermuda
   (ii) Bermuda

(d) Title of Class of Securities

   	Common Stock

(e) CUSIP Number

   	29664W105

Item 3.

	Not applicable.

Item 4. Ownership.

(a) Amount beneficially owned:

   (i)	4,468,835
   (ii)	4,468,835

(b) Percent of class:

   (i) 	6.1%
   (ii)	6.1%

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote

   (i)	.........
   (ii) .........

(ii) Shared power to vote or to direct the vote

   (i)	4,468,835
   (ii)	4,468,835

(iii) Sole power to dispose or to direct the disposition of

   (i)	.........
   (ii) .........

(iv) Shared power to dispose or to direct the disposition of

   (i)	4,468,835
   (ii)	4,468,835

Item 5. Ownership of Five Percent or Less of a Class

	Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

	Meditor European Master Fund Ltd., an investment management client
	and subsidiary of Meditor Group Ltd., has the right to receive and the power
	to direct the receipt of dividends from, and the proceeds
	from the sale of, the securities identified herein.

Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on By the Parent Holding Company or Control Person.

	Not applicable.

Item 8. Identification and Classification of Members of the Group

	Not applicable.

Item 9. Notice of Dissolution of Group

	Not applicable.

Item 10. Certification

	By signing below each of the undersigned certifies that,
	to the best of their knowledge and belief, the securities referred to
	above were not acquired and are not held for the purpose
	of or with the effect of changing or influencing the control
	of the issuer of the securities and were not acquired and are not held
	in connection with or as a participant in any transaction
	having that purpose or effect.

SIGNATURE

	After reasonable inquiry and to the best of our knowledge and belief,
	we certify that the information set forth in this statement is true,
	complete and correct.

	January 4, 2023

	Meditor Group Ltd.

     By	B. Desmond (Director)

	Meditor European Master Fund Ltd.

     By	B. Desmond (Director)

=============================================================================

JOINT FILING AGREEMENT

	The undersigned each hereby agree to the joint filing of statements
	on Schedule 13G (and amendments thereto) relating to the common stock
	of Esperion Therapeutics, Inc.

	January 4, 2023

	Meditor Group Ltd.

     By	B. Desmond (Director)

	Meditor European Master Fund Ltd.

     By	B. Desmond (Director)

```